The Clinical Pharmacokinetics of Escitalopram
The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Escitalopram is the (S)-enantiomer of the racemic selective serotonin reuptake inhibitor antidepressant citalopram. Clinical studies have shown that escitalopram is effective and well tolerated in the treatment of depression and anxiety disorders. Following oral administration, escitalopram is rapidly absorbed and reaches maximum plasma concentrations in approximately 3-4 hours after either single- or multiple-dose administration. The absorption of escitalopram is not affected by food. The elimination half-life of escitalopram is about 27-33 hours and is consistent with once-daily administration. Steady-state concentrations are achieved within 7-10 days of administration. Escitalopram has low protein binding (56%) and is not likely to cause interactions with highly protein-bound drugs. It is widely distributed throughout tissues, with an apparent volume of distribution during the terminal phase after oral administration (V(z)/F) of about 1100L. Unmetabolised escitalopram is the major compound in plasma. S-demethylcitalopram (S-DCT), the principal metabolite, is present at approximately one-third the level of escitalopram; however, S-DCT is a weak inhibitor of serotonin reuptake and does not contribute appreciably to the therapeutic activity of escitalopram. The didemethyl metabolite of escitalopram (S-DDCT) is typically present at or below quantifiable concentrations. Escitalopram and S-DCT exhibit linear and dose-proportional pharmacokinetics following single or multiple dos…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Neuropsychological testing started 3 h following pill administration to achieve peak plasma escitalopram concentrations [21].”
From Dissociable effects of acute SSRI (escitalopram) on executive, learning and emotional functions in healthy humans (2018) · cites this paper as [21]
Citations
Cites
Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism
Desta, Z., Zhao, X., Shin, J.-G., & Flockhart, D. A. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241120-00002 · Cited by 942
Owens, M. J., Knight, D. L., & Nemeroff, C. B. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01145-3 · Cited by 516
Fluvoxamine is a potent inhibitor of cytochrome P4501A2
Brøsen, K., Skjelbo, E., Rasmussen, B. B., Poulsen, H. E., & Loft, S. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90272-x · Cited by 374
Hemeryck, A., & Belpaire, F. (2002) · Current Drug Metabolism · doi:10.2174/1389200023338017 · Cited by 368
Fixed-Dose Trial of the Single Isomer SSRI Escitalopram in Depressed Outpatients
Burke, W. J., Gergel, I., & Bose, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0410 · Cited by 350
The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer
Hyttel, J., B�ges�, K. P., Perregaard, J., & S�nchez, C. (1992) · Journal of Neural Transmission · doi:10.1007/bf01244820 · Cited by 323
Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression
Mace, S., & Taylor, D. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.5.917 · Cited by 315
Inhibition of P-Glycoprotein by Newer Antidepressants
Weiss, J., Dormann, S.-M. G., Martin-Facklam, M., Kerpen, C. J., Ketabi-Kiyanvash, N., & Haefeli, W. E. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.046532 · Cited by 292
Sánchez, C., Bergqvist, P. B. F., Brennum, L. T., Gupta, S., Hogg, S., Larsen, A., & Wiborg, O. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1364-z · Cited by 265
Escitalopram versus citalopram: the surprising role of the R-enantiomer
S�nchez, C., B�ges�, K., Ebert, B., Reines, E., & Braestrup, C. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1865-z · Cited by 248
Research works printed but not linked: 2
- von Moltke, 2001, Drug Metab Dispos, 29, 1102
- Periclou, 2003, Pharmacotherapy, 23, 1361
Cited by
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance: Part I
Zhou, S.-F. (2009) · Clinical Pharmacokinetics · doi:10.2165/11318030-000000000-00000 · Cited by 756
King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., Donnelly, C. L., Anagnostou, E., Dukes, K., Sullivan, L., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.30 · Cited by 482
Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review
Edinoff, A. N., Akuly, H. A., Hanna, T. A., Ochoa, C. O., Patti, S. J., Ghaffar, Y. A., Kaye, A. D., Viswanath, O., Urits, I., Boyer, A. G., et al. (2021) · Neurology International · doi:10.3390/neurolint13030038 · Cited by 440
Psychiatric pharmaceuticals in the environment
Calisto, V., & Esteves, V. I. (2009) · Chemosphere · doi:10.1016/j.chemosphere.2009.09.021 · Cited by 410
Metadata
- Authors
- Rao, N.
- Corresponding author
- Rao, Niranjan
- Venue
- Clinical Pharmacokinetics
- Published
- 2007
- Volume
- 46
- Issue
- 4
- Pages
- 281-290
- ISSN
- 0312-5963 (ISSN-L)
- OpenAlex
- W1993067969
- Cited by
- 256
- References
- 55
- Citations by year
- 2026: 11 · 2025: 27 · 2024: 14 · 2023: 20 · 2022: 19 · 2021: 15 · 2020: 14 · 2019: 9 · 2018: 11 · 2017: 9 · 2016: 6 · 2015: 13 · 2014: 9 · 2013: 13 · 2012: 12
- FWCI
- 1.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Pharmacokinetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Keywords
- escitalopram, pharmacokinetics, selective serotonin reuptake inhibitors, citalopram, drug metabolism, CYP2C19, CYP2D6, CYP3A4, P-glycoprotein, food effect, liver dysfunction, antidepressants, anxiety disorders, depression
- MeSH terms
- Adolescent, Adult, Age Factors, Aged, Anxiety Disorders, Child, Depression, Drug Interactions, Humans, Liver Diseases, Sex Factors, Citalopram, Selective Serotonin Reuptake Inhibitors, Renal Insufficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Clinical Pharmacokinetics of Escitalopram. https://app.cochat.ai/papers/10.2165/00003088-200746040-00002
- The paper
- Rao, N. (2007). The Clinical Pharmacokinetics of Escitalopram. Clinical Pharmacokinetics. https://doi.org/10.2165/00003088-200746040-00002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.